SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77328.19
516.33 (-0.66%)

Filter

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
91	Mankind Pharma Ltd.	Q V PT	1,00,200 Mid Cap	2,427.15 (2.18%)	57.56	6.14	14.65	12.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
92	Vijaya Diagnostic Centre Ltd.	Q V PT	12,359 Small Cap	1,278.15 (5.73%)	67.58	12.88	15.00	18.43	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
93	Themis Medicare Ltd.	Q V PT	902 Small Cap	97.96 (-0.86%)	N/A	3.04	15.00	7.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
94	Fortis Healthcare Ltd.	Q V+ PT	71,880 Mid Cap	952.10 (0.49%)	438.47	7.77	15.55	-22.45	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
95	Astrazeneca Pharma India Ltd.	Q V+ PT	21,223 Small Cap	8,489.25 (-0.54%)	106.22	25.66	15.59	20.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
96	Rainbow Childrens Medicare Ltd.	Q V PT	13,252 Small Cap	1,304.85 (0.98%)	53.51	7.96	15.91	24.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
97	Anuh Pharma Ltd.	Q V PT	843 Small Cap	84.15 (1.45%)	19.88	2.44	16.60	20.73	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
98	Gufic Biosciences Ltd.	Q V PT	3,008 Small Cap	300 (0.93%)	58.97	4.63	16.69	24.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
99	Global Health Ltd.	Q V PT	32,278 Small Cap	1,200.60 (-1.14%)	70.14	8.41	16.83	34.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
100	Supriya Lifescience Ltd.	Q V PT	5,697 Small Cap	707.80 (1.06%)	30.43	4.98	17.45	18.30	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
101	Caplin Point Laboratories Ltd.	Q V PT	14,118 Small Cap	1,857.35 (-0.47%)	23.11	4.27	17.55	21.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
102	Syncom Formulations (India) Ltd.	Q V PT	1,383 Small Cap	14.71 (-1.61%)	20.39	3.55	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
103	Dr Agarwals Eye Hospital Ltd.	Q V PT	2,465 Small Cap	5,101.30 (0.74%)	35.04	7.37	17.68	31.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
104	Sai Life Sciences Ltd.	Q V+ PT	23,680 Small Cap	1,116.85 (2.55%)	70.21	9.62	17.75	11.20	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
105	JB Chemicals & Pharmaceuticals Ltd.	Q V+ PT	34,551 Small Cap	2,151.90 (0.49%)	47.27	8.81	17.81	19.45	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
106	Jupiter Life Line Hospitals Ltd.	Q V PT	8,192 Small Cap	1,249.40 (-0.78%)	44.24	5.3	18.02	36.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
107	Windlas Biotech Ltd.	Q V PT	1,732 Small Cap	820.55 (-4.24%)	27.11	3.29	18.24	17.22	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
108	Natco Pharma Ltd.	Q V PT	21,028 Small Cap	1,174 (1.72%)	13.28	2.35	18.26	32.57	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
109	Concord Biotech Ltd.	Q V PT	12,294 Small Cap	1,175.15 (-1.84%)	40.08	6.62	18.56	18.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
110	KMC Speciality Hospitals (India) Ltd.	Q V PT	1,557 Small Cap	95.47 (6.85%)	N/A	N/A	19.21	12.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
111	Poly Medicure Ltd.	Q V PT	16,736 Small Cap	1,651.20 (-1.69%)	49.77	5.74	19.91	26.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
112	Innova Captab Ltd.	Q V PT	5,010 Small Cap	875.45 (1.44%)	59.01	5.63	20.74	22.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
113	Kwality Pharmaceuticals Ltd.	Q V+ PT	1,817 Small Cap	1,751.25 (2.10%)	31.47	5.8	21.70	37.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
114	Eris Lifesciences Ltd.	Q V PT	19,212 Small Cap	1,386.75 (0.22%)	44.4	5.29	21.92	3.58	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
115	Marksans Pharma Ltd.	Q V PT	8,968 Small Cap	197.90 (-2.58%)	37.37	5.92	22.06	32.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
116	Anthem Biosciences Ltd.	Q V+ PT	44,069 Mid Cap	784.55 (0.73%)	86.43	14.75	23.81	40.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
117	Sigachi Industries Ltd.	Q V+ PT	841 Small Cap	22.01 (4.96%)	N/A	1.7	24.05	7.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
118	Dr. Agarwals Health Care Ltd.	Q V PT	14,404 Small Cap	454.45 (0.70%)	113.48	7.24	26.38	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
119	Yatharth Hospital & Trauma Care Services Ltd.	Q V+ PT	8,312 Small Cap	862.60 (4.86%)	84.73	4.96	27.90	137.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
120	Rubicon Research Ltd.	Q V+ PT	15,761 Small Cap	954.70 (0.29%)	93.8	12.15	32.49	25.95	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Metropolis Health.	550.30	8.83%
Shree Ganesh Remed.	530.60	8.65%
KMC Speciality Hosp	95.47	6.85%
Guj. Kidney & Super	139.85	6.84%
Nectar Lifesciences	14.39	5.89%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Indoco Remedies	228.20	-9.17%
Windlas Biotech	820.55	-4.24%
Panacea Biotec	388.15	-4.16%
Fermenta Biotech	288.70	-4.07%
Lupin	2,377.90	-3.33%

News about Top Pharma Companies in India

May, 2026

Rainbow Children's Medicare informs about update on ongoing tax litigation

Pursuant to Regulation 30 of the Listing Regulations, read with Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (the Master Circular), and in furtherance to earlier disclosure dated May 31, 2024 regarding the receipt of demand notice under Section 74(5) of CGST Act, 2017 from Additional Director, Directorate General of GST Intelligence, Bengaluru Zonal Unit, Rainbow Children's Medicare has informed that the Company has received an order from the Principal Commissioner of Customs and Central Tax (Appeals-1) by post on 7th May 2026, whereby the appeal filed by the Company against the said demand notice dated May 29, 2024 has been disallowed and the impugned order has been upheld. The requisite details in terms of Schedule III to the SEBI Listing Regulations read with the Master Circular are enclosed as Annexure 1. A copy of this intimation is also being made available on the website of the Company. Any further update in this connection will be submitted to the Stock Exchanges in due course.

The above information is a part of company’s filings submitted to BSE.

May, 2026

Innova Captab - Quaterly Results

The Sales for the quarter ended March 2026 of Rs. 3582.77 millions rose by 47.73% from Rs. 2425.22 millions.Modest increase of 23.57% in the Net Profit was reported from. 171.25 millions to Rs. 211.62 millions.Operating profit surged to 413.19 millions from the corresponding previous quarter of 325.36 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	3582.77	2425.22	47.73	12988.14	9580.61	35.57	12988.14	9580.61	35.57
Other Income	26.80	43.56	-38.48	132.43	167.75	-21.06	132.43	167.75	-21.06
PBIDT	413.19	325.36	26.99	1646.10	1390.74	18.36	1646.10	1390.74	18.36
Interest	39.81	18.69	113.00	154.21	21.68	611.30	154.21	21.68	611.30
PBDT	373.38	306.67	21.75	1491.89	1369.06	8.97	1491.89	1369.06	8.97
Depreciation	94.03	78.12	20.37	373.67	170.15	119.61	373.67	170.15	119.61
PBT	279.35	228.55	22.23	1118.22	1198.91	-6.73	1118.22	1198.91	-6.73
TAX	67.73	57.30	18.20	281.30	304.21	-7.53	281.30	304.21	-7.53
Deferred Tax	58.38	29.89	95.32	103.65	84.21	23.09	103.65	84.21	23.09
PAT	211.62	171.25	23.57	836.92	894.70	-6.46	836.92	894.70	-6.46
Equity	572.25	572.25	0.00	572.25	572.25	0.00	572.25	572.25	0.00
PBIDTM(%)	11.53	13.42	-14.04	12.67	14.52	-12.69	12.67	14.52	-12.69

May, 2026

Caplin Point gains as its arm gets USFDA’s approval for Calcium Gluconate Injection

Calcium Gluconate Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia

May, 2026

Caplin Point’s arm gets USFDA’s approval for Calcium Gluconate Injection

Calcium Gluconate Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia

May, 2026

Rainbow Children's Medicare informs about updates

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), Rainbow Children's Medicare has informed that the Company has inaugurated the following new healthcare facilities: 1. A new 60 beds Spoke Hospital, located at HRBR Layout, Hennur Junction, Karnataka; and 2. An IVF Centre under the brand name BirthRight Fertility, an extension of Marathahalli hub located at Mahadevpura, Karnataka. The requisite disclosures as required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed herewith as Annexure - A - Disclosure relating to the Spoke Hospital at HRBR layout, Hennur Junction & the IVF Centre, BirthRight Fertility, Mahadevpura. Further, a press release in connection with the inauguration of the above facilities is enclosed as Annexure - B.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Sai Life Sciences informs about disclosure

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) read with SEBI Circular on the Industry Standards Note on Regulation 30 dated 25 February 2025, Sai Life Sciences has informed that an Order dated 29th April, 2026 was passed by the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi u/s 107 (11) of the Central Goods and Services Tax Act, 2017 and the Karnataka Goods and Services Tax Act, 2017. The details as required in terms of Regulation 30 read with Schedule III of the Listing Regulations is enclosed as Annexure - I.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Jubilant Pharmova Ltd.	16,065 Crore
2	Suven Life Sciences Ltd.	5,911 Crore
3	Aster DM Healthcare Ltd.	38,465 Crore
4	Panacea Biotec Ltd.	2,377 Crore
5	Sanofi India Ltd.	7,664 Crore
6	Nectar Lifesciences Ltd.	280 Crore
7	Novartis India Ltd.	2,747 Crore
8	Aurobindo Pharma Ltd.	86,452 Crore
9	Apollo Hospitals Enterprise Ltd.	1,16,392 Crore
10	Sun Pharma Advanced Research Company Ltd.	5,609 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	26,661	56,654	37.17	12.91	26.02	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,380	1,48,251	65.25	16.32	36.87	26.68
Ajanta Pharma Ltd. (S)	Very Good	3,032	37,883	35.87	8.37	24.25	24.45
Lupin Ltd. (M)	Somewhat Good	2,378	1,08,721	20.39	4.84	11.79	20.83
Zydus Lifesciences Ltd. (M)	Very Good	939	94,475	19.13	3.60	11.91	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,229	66,373	110
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,364	66,722	67.00
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	40.02
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,380	1,48,251	37.62
Gland Pharma Ltd. (S)	Very Good	1,904	31,377	34.73
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	47.50	8.85	30.00	17.81
Mankind Pharma Ltd. (M)	Very Good	2,427	1,00,200	58.82	6.28	35.25	14.65
Laurus Labs Ltd. (M)	Very Good	1,229	66,373	74.68	12.52	37.46	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,293	1,07,942	19.38	2.90	11.65	13.26
Ajanta Pharma Ltd. (S)	Very Good	3,032	37,883	35.87	8.37	24.25	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	939	94,475	19.13	3.60	11.91	30.57
Cipla Ltd. (L)	Very Good	1,348	1,08,865	23.95	3.24	14.44	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,847	4,43,229	40.61	5.46	22.21	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,293	1,07,942	19.38	2.90	11.65	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	47.50	8.85	30.00	19.45

You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Rainbow Children's Medicare informs about update on ongoing tax litigation

Innova Captab - Quaterly Results

Caplin Point gains as its arm gets USFDA’s approval for Calcium Gluconate Injection

Caplin Point’s arm gets USFDA’s approval for Calcium Gluconate Injection

Rainbow Children's Medicare informs about updates

Sai Life Sciences informs about disclosure

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.